Erythropoietin both protects from and reverses experimental diabetic neuropathy
Roberto Bianchi(AOL (United States)), Pietro Ghezzi(Brighton and Sussex Medical School), Anthony Cerami(Araim Pharmaceuticals (United States)), Michael Brines(Northwell Health), Costanza Savino(University of Messina), M. Borgna(University of Milan), Arzu Kanık(Mersin Üniversitesi), Giuseppe Lauria(University of Milan), Ülkü Çömelekoğlu(Mersin Üniversitesi), Belgin Büyükakıllı(University of Milan), Guido Cavaletti(Bellvitge University Hospital), N Oggioni(University of Milano-Bicocca), Raffaella Lombardi(Apple (Israel)), Burak Çimen(University of Milan), Cengiz Tataroğlu(University of Milan)
Cited by 252
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k